ImClone SEC charges coming
Executive Summary
The Securities & Exchange Commission is "considering recommending" civil action against ImClone for its description of a refuse-to-file letter for the oncologic agent Erbitux, company says June 19. ImClone can respond in writing under "Wells notice" process before SEC staff makes formal recommendation. The notice comes a week after former ImClone CEO Samuel Waksal was charged with insider trading, and the House Energy & Commerce/Oversight Subcommittee held a hearing on the review of the agent....